Anita Gheller-Rigoni, DO
Allergy & Immunology · Oshkosh, WINPI 1073543096
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175 of the $257 with a category attached, or 68.2%. Aimmune Therapeutics, Inc. accounts for 68.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $189 and has fallen 68.8% since, to $59 in 2025. That places this record below the midpoint for allergy & immunology clinicians in WI, where the typical reported total is $494.
Across 5 payments — averaging $51.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aimmune Therapeutics, Inc.$175
- Amgen$34
- Ionis Pharmaceuticals, Inc.$25
- Pfizer$14
- Bio Products Laboratory USA, Inc.$8
What the payments were for
- Speaking & faculty fees$17568%
- Food & beverage$146%
- Education$6726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aimmune Therapeutics, Inc. | 1 | $175 |
| Amgen | 1 | $34 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Pfizer | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PALFORZIA$175
How this compares
$257 in reported general payments places this provider in the 30th percentile of 55 allergy & immunology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 59 | $250,552 |
| TezspireTezepelumab-Ekko | 38 | $179,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 173 | $134,511 |
| Dupixent SyringeDupilumab | 25 | $102,455 |
| Dupixent PenDupilumab | 15 | $68,229 |
| Advair HfaFluticasone Propion/Salmeterol | 98 | $54,195 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $29,885 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 42 | $27,485 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $27,288 |
| DuleraMometasone/Formoterol | 53 | $23,351 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $22,882 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 104 | $22,607 |
| SymbicortBudesonide/Formoterol Fumarate | 50 | $19,736 |
| Spiriva RespimatTiotropium Bromide | 18 | $18,118 |
| Spiriva HandihalerTiotropium Bromide | 23 | $13,427 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Oshkosh
- William BusseMadison$928K
- Jared DarveauxOnalaska$287K
- Don BuksteinFitchburg$257K
- Allan LuskinMadison$51K
- Monica VasudevSheboygan$25K
- Heidi ZafraMilwaukee$7K
- Christopher MjaanesNeenah$6K
- Sudip RingwalaKenosha$6K
- Steven CohenWest Allis$5K
- Karen KonzAppleton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.